These are some of the benefits of “in silico medicine,” or the testing of drugs and treatments on virtual organs or body systems to predict how a real person will respond to the therapies. With virtual organs, the modeling begins by feeding anatomical data drawn from noninvasive high-resolution imaging of an individual's actual organ into a complex mathematical model of the mechanisms that govern that organ's function. The agency has also published guidance for designing trials of drugs and devices that include virtual patients. The philosophy behind in silico medicine is not new. In silico medicine must be able to deliver cost-effective value for patients, clinicians and health care organizations to accelerate their adoption of the technology.